The development of anti‑infective therapies and vaccines requires robust preclinical models capable of capturing both pathogen control and host immune response. Infectious diseases involve complex interactions between pathogens, innate and adaptive immunity, and tissue‑specific responses, making the generation of meaningful efficacy and pharmacodynamic data particularly challenging.
At CER Groupe, we design and conduct customised preclinical efficacy studies in infectious diseases, integrating in vivo infection models with supporting in vitro and cell‑based assays. As both a research centre and a CRO, we support pharmaceutical and biotechnology innovators with translational data to guide candidate selection, dose optimisation and progression toward clinical development.
Our approach to infectious disease efficacy is built on:
This strategy supports programmes from early proof‑of‑concept to advanced preclinical optimisation, across small molecules, biologics, vaccines, immune‑based therapies and innovative anti‑infective approaches.
CER Groupe offers a portfolio of established and adaptable in vivo infection models, covering bacterial and viral pathogens as well as localised and systemic infections.
These assays help characterise host immune responses and support biomarker selection.
To support therapies targeting host‑directed or immune‑modulating mechanisms:
To ensure selectivity and interpret therapeutic index:
These assays are particularly relevant for anti‑infective and vaccine programmes, where host‑cell safety is critical.
Infectious disease studies at CER Groupe integrate multi‑level pharmacodynamic readouts, including:
This integrated strategy strengthens translational relevance and supports alignment with clinical infectious disease endpoints.
For programmes requiring non‑standard pathogens, routes of infection or immune readouts, CER Groupe offers custom model development and co‑development, including:
This approach is particularly suited for first‑in‑class anti‑infective strategies and innovative vaccine concepts.
